Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence or rituximab

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 129-133

  Feugier, P ^a   Virion, J M ^a   Tilly, H ^b   Haioun, C ^c   Marit, G ^d   Macro, M ^e   Bordessoule, D ^f   Recher, C ^g   Blanc, M ^h   Molina, T ⁱ   Lederlin, P ^a   Coiffier, B ^j  

^a CHU NANCY BRABOIS   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h CENTRE HOSPITALIER DE CHAMBÉRY   (France)

ⁱ Service de Pathologie   (France)

^j Service D H Modynamique H Pital Cardiologique   (France)

more..

Author keywords

Aggressive non Hodgkin's lymphoma; Central nervous system occurence; Risk factors; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DIFFUSION; DRUG EFFICACY; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INCIDENCE; INJECTIONS, SPINAL; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 9144223630     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh013     Document Type: Article

References (15)

1. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
2. Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78: 145-149.
3. Patte C, Michon J, Frappaz D et al. Therapy of Burkitt and B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP in children and adults. Bailleres Clin Haematol 1994; 7: 339-348.
4. Hopfinger G, Heinz R, Koller E et al. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma. Eur J Haematol 1995; 55: 223-227.
5. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cis-platin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-121
6. Harjunpaa A, Wiklund T, Collan J et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001; 42: 731-738.
7. Rubenstein JL, Rosenberg J, Damon L. High-dose methotrexate plus rituximab (Anti CD20) monoclonal antibody in the treatment of primary CNS lymphoma. Society for Neuro-Oncology Fourth Annual Meeting, Scottsdale, AZ, USA, November 1999 (Abstr).
8. Bashir RM, Bierman PJ, Vose JM et al. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 1991; 14: 478-482.
9. Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13: 1099-1107.
10. Van Besien K, Ha CS, Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178-1184.
11. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000; 11: 685-690.
12. Bos GM, Van Putten WL, Van der Holt B et al. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Ann Oncol 1998; 9: 191-194.
13. Zinzani PL, Magagnoli M, Frezza G et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999; 32: 571-576.
14. Tilly H, Lepage E, Coiffier B et al. A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non Hodgkin's lymphoma: the LNH93-5 study. Blood 2000; 96: 832a (Abstr 3596).
15. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466-468.